EC Approves Teva's Generic Version Of Neupogen

Law360 (September 16, 2008, 12:00 AM EDT) -- In a still relatively rare approval of a biosimilar drug, Israeli generic-drug maker Teva Pharmaceutical Industries Ltd. announced Tuesday that the European Commission had approved a copycat version of Amgen Inc.'s neutropenia treatment Neupogen.

Teva's human granulocyte colony stimulating factor, or G-CSF, product is the first biosimilar G-CSF to receive a marketing authorization by the EC, according to the company.

The EC's approval reportedly comes just a few months after the scientific committee of the European Medicines Evaluation Agency issued a positive opinion for the product....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.